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Abstract
Background: Video-assisted thoracoscopic surgery (VATS) lobectomy is a newly developed type of surgery for lung
cancer and has been demonstrated obvious minimally-invasive advantages compared with traditional thoracotomy.
Theoretically, that less trauma leads to quicker recovery and may facilitate administration of adjuvant
chemotherapy. We tested this hypothesis in this study.
Methods: One hundred and ten NSCLC patients underwent lobectomy and adjuvant chemotherapy from June
2004 to June 2010 was analyzed. The baseline characteristic criteria, variables related to surgery and accomplishing
status of chemotherapy were analyzed.
Results: All 110 patients underwent lobectomy through VATS (n = 54) or thracotomy (n = 56) and adjuvant
chemotherapy. There was no significant difference in patients’ age, preoperative pulmonary function, co-morbidity,
pathologic staging between the two groups, whereas, blood loss, operation time and postoperative complications,
chest tube duration and length of stay were less in VATS group. There were no significant differences in time to
initiation chemotherapy. Cases in VATS group received more cycles of chemotherapy (3.6 vs. 3.0, p = 0.002). A
higher proportion of patients received full dose on schedule in VATS group (57.4% vs. 33.9%, p = 0.013) and a
higher proportion of patients completed ≥75% planed dose, (88.9% vs. 71.4%, p = 0.022); slightly higher proportion
of patients in thoracotomy group had grade 3 or more toxicity (20.4% vs. 35.7%, p = 0.074).
Conclusions: Patients underwent lobectomy by VATS have better compliance and fewer delayed or reduced dose
on adjuvant chemotherapy than those by thoracotomy.
Keywords: video-assisted thoracoscopic surgery (VATS), lobectomy, non-small cell lung cancer (NSCLC), adjuvant
chemotherapy
Background
Adjuvant cisplatin-based chemotherapy is recommended
for patients with stages II, IIIA, and a subgroup of IB
non-small cell lung cancer (NSCLC), based on the posi-
tive results of several large randomized trials and a meta-
analysis [1-4]. Among these studies, the JBR10 study
reported that postoperative chemotherapy increased 15
percent at 5 years survival rate in lung cancer patients
(mainly for patients with stage II disease) [2]; ANITA
study reported that the absolute overall survival benefit
with adjuvant chemotherapy was 8.6 percent at five years
and 8.4 percent at seven years (mainly for patients with
stage II and IIIA disease) [3]. Subgroup analysis of
CALGB 9633 indicated that lung cancer patients in stage
IB with tumor diameter more than 4 cm may benefit
from postoperative chemotherapy [4].
Although no direct evidence, it is postulated that early
and full-dose adjuvant chemotherapy may maximize the
benefit. However, patients receiving lobectomy through
conventional thoracotomy sometimes have delayed
* Correspondence: jwangmd@yahoo.com
Department of Thoracic Surgery, Center for Mini-invasive Thoracic Surgery,
People’s Hospital, Peking University, #11 Xizhimen South Street, Beijing,
China, 100044
Jiang et al. World Journal of Surgical Oncology 2011, 9:170
http://www.wjso.com/content/9/1/170 WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
© 2011 Jiang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.adjuvant therapy due to slow recovery, and not infre-
quently, discontinue treatment because of worsening of
performance status (PS) [4]. During the past decade,
m o r ea n dm o r ee v i d e n c es h o w e dt h a tv i d e o - a s s i s t e d
thoracoscopic surgery (VATS) lobectomy, also referred
to as thoracoscopic lobectomy, can be an alternative
surgical approach for lung cancer patients [5-12]. The
advantages of VATS lobectomy include remission of
post-operative pain, less releasing of inflammatory factor
and less effect on pulmonary functions, fewer complica-
tions and rapid recovery [6-10], without compromising
the long term survival and disease free survival [11,12].
However further studies are needed to evaluate the
minimally-invasiveness of VATS on adjuvant che-
motherapy delivery.
In this study, we retrospectively analyzed 110 NSCLC
patients who received thoracotomy or VATS lobectomy
since June 2004 in our hospital. We compared their
accomplishing status of postoperative chemotherapy to
investigate whether the postoperative chemotherapy com-
pliance is better in patients underwent VATS than those
through thoracotomy.
Materials and methods
1. Patient Selection
The medical record of 497 NSCLC patients who underwent
lobectomy by VATS (n = 243) or by thoracotomy (n = 254)
from June 2004 to June 2010 in Peking University People’s
Hospital were reviewed. The indications for VATS lobect-
omy were as follows: clinical stage I or II peripheral non-
small cell lung cancer without involvement of chest wall;
no calcified hilar lymph nodes on CT scan; tumor less than
5 cm in diameter. To make the thoracotomy group com-
parable, only patients meet the same preoperative criteria
were selected. Patients underwent lobectomy and systemic
mediastinal lymph nodes dissection, and at least one cycle
of adjuvant chemotherapy in our institution were elligible
for this the current study, patients received neoadjuvant
therapy, bi-lobectomy or pneumonectomy were excluded.
As intention to treat principle, conversion-to-thoracotomy
cases were analyzed in the VATS group. Finally, 110
patients were enrolled, of them 54 patients underwent
VATS, the other 56 patients, thoracotomy. There were 2
conversion-to-thoracotomy cases in VATS group, of them,
one case was due to inflammation induced peri-vascular
fibrosis and interlobar lymph node calcification; the other
conversion was caused by intra-operative bleeding. This
study was conducted with Institutional Review Board
approval. Consent from patients was waived because
patients were not identified individually.
2. Surgical Technique
VATS lobectomy was performed in 54 patients in this
group (including two cases of conversion to thoracotomy).
We used three-port technique for anatomic lobectomy
without rib-spreading, the utility incision was usually 4-5
cm in length in order to retrieve the specimen [13]. Sys-
temic lymph nodes dissection was also carried out with
the standard identical to thoracotomy surgery. Open
lobectomy was performed on 56 patients with a 15-20 cm
lateral incision in the 4th or 5th intercostal space without
rib transection, but partial spreading of the serratus and
latissimus muscles. Thoracotomy incision was closed with
running pericostal suture as the first layer, while VATS
incisions, the muscular.
Pathologic staging was performed according to the 6th
International Staging System for Lung Cancer. Patients
were followed from the date of the operation until either
death or April 2011. Survival was calculated, and adverse
events, including all causes of death, were evaluated.
3. Chemotherapy administered
Adjuvant chemotherapy was recommended to patients with
pathologic stage Ib or higher disease after recovery from
surgery and ECOG performance status (PS) 0-1. The che-
motherapy regimens included gemcitabine (1250 mg/m
2,
d1, d8,) plus cisplatin (75 mg/m
2, d1) every 3 weeks, or
paclitaxel (175 mg/m
2 over 3 hours) plus carboplatin (area
under curve [AUC] 5) every 3 weeks, and it was chosen by
the treating physician. The maximum number of cycles was
4. Dose reduction or dose delay were decided according to
objective criteria (white blood cell count, absolute neutro-
phil count and serum creatinine, side effect on gastrointest-
inal, liver and neurologic systems) and subjective criteria
(PS score). Usually, the treatment would be delayed or dose
reduced for grade 3 or higher toxicity and PS > = 2. The
toxicity was graded according to the NCI Common Toxi-
city Criteria for Adverse Events (version 2.0).
4. Examination of compliance
Baseline characteristics including age, gender, ECOG per-
formance status, co-morbidities, pulmonary function, and
operative parameters such as operation time, blood loss,
chest tube duration, length of stay and post operative
complications, pathologic staging were compared between
the two groups. Outcomes were measured with number of
cycles of chemotherapy, mean dose administered to each
patient; time to initiate adjuvant chemotherapy, propor-
tion of patients received delayed or reduced doses and
treatment-related toxicity.
5. Statistical methods
Variables were compared between the VATS and the
thoracotomy groups, using Student t test for continuous
variables, and either chi-square or Fisher’se x a c tt e s tf o r
categorical variables. Survival rates were calculated by
life-table analysis. Kaplan-Meier survival curves were
compared using the log-rank test for univariate analysis.
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cally significant. All statistical analyses were performed
using SPSS 11.5 software.
Results
1. Patient characteristics
The baseline characteristics of the patients are shown in
Table 1. There was no significant difference in age, gen-
der, ECOG performance status, pulmonary function and
co-morbidities between the two groups. In VATS group,
there were more adenocarcinoma patients (p < 0.001).
With respect to perioperative parameters, the VATS
group had less operation time and blood loss (p <
0.001), as well as chest tube duration (p = 0.025) and
length of stay (p = 0.043). The incidence rate of post-
operative complications was also slightly lower in VATS
group than that in thoracotomy group, especially atrial
fibrillation (Table 2).
2. Chemotherapy compliances
The chemotherapy regimens administered in two
groups were similar (p = 0.577). But patients in VATS
group completed more cycles of chemotherapy (3.6 vs.
3.0, p = 0.002). There were more patients completed
all four cycles at full planned dose on schedule in
VATS group (57.4% vs. 33.9%, p = 0.013) and a higher
proportion of patients completed ≥75% planed dose,
(88.9% vs. 71.4%, p = 0.022). The mean dose adminis-
tered in VATS group was more than that in thoracot-
omy group. Reasons for dose delay or dose reduction
in our series were toxicity and patients’ refusal.
Patients in VATS group were less likely to experience
grade 3 or 4 toxicities than those in thoracotomy
group (20.4% vs. 35.7%, p = 0.074) (Table 3).
All the Grade 3/4 toxicities of chemotherapy are listed
in Table 4 according to NCI-CTC grade. The VATS
group was less likely to suffer from hematologic (16.7%
vs. 33.3%, p = 0.046) and non-hematologic toxicities
(11.1% vs. 26.8%, p = 0.037) (Table 4).
Although the pathologic type was different in the two
groups, no significant differences of the compliance of
the adjuvant chemotherapy were noted between adeno-
carcinoma and squamous cell carcinoma or other histol-
ogy (Table 5).
3. Follow-up
Follow-ups were completed for 101 patients (101/110).
Patients were followed up until death. The median follow-
up period was 30 months (2-82 months). Overall 2-year
survival rates were 91.0% and 70.6%, and disease-free 2-
year survival rates were 70.9% and 62.7% for the VATS
and thoracotomy groups, respectively. There was a trend
toward better overall and disease-free survival in the
VATS group, but the difference did not reach statistical
significance.
Discussion
After the publication of survival results of several adju-
vant chemotherapy trials, adjuvant chemotherapy has
become an important part of multimodality treatment for
non-small cell lung cancer [1-4]. It is postulated that bet-
ter compliance of chemotherapy may increase its efficacy
and therefore would bring survival benefits [14]. If so,
better compliance of adjuvant chemotherapy would be of
therapeutic value. VATS lobectomy is a newly developed
approach for lung cancer in the past two decades and has
shown significant minimally-invasive advantages over tra-
ditional thoracotomy, mainly manifesting fewer traumas
Table 1 Comparison of general states between two groups of patients before chemotherapy
VATS
n=5 4
Thoracotomy
n=5 6
p value
Gender (male), no. (%) 33(61.1) 38(67.9) 0.460
Age (year) 62.9 ± 9.6 61.9 ± 11.1 0.596
ECOG Performance Status, no. (%) 0.862
0 29(53.7) 31(55.4)
1 25(46.3) 25(44.6)
Preoperative complications, no. (%)
Hypertension 20(37.0) 13(23.2) 0.114
Diabetes mellitus 4(7.4) 2(3.6) 0.434
Coronary heart disease 6(11.1) 3(5.4) 0.316
Disease of respiratory system 6 (11.1) 11(19.6) 0.216
Preoperative pulmonary function (percent of predicted value)
FVC 100.8 ± 14.1 99.7 ± 19.0 0.749
FEV1 97.1 ± 15.3 97.1 ± 24.1 0.987
DLCO 85.8 ± 16.3 90.4 ± 19.5 0.174
Note: Diseases of respiratory system include old pulmonary tuberculosis, pulmonary interstitial disease and COPD
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rapid recovery [5-10]. It is unknown whether the mini-
mally-invasive natures of the VATS can translate into
better compliance of adjuvant chemotherapy. At the time
we finished this manuscript, there was just one publica-
tion of a retrospective small study with similar design by
Petersen et al, comparing the adjuvant chemotherapy
state of 43 patients received lobectomy through thoracot-
omy and 57 patients underwent VATS. Their preliminary
results indicated that the patients receiving VATS have
better compliance of adjuvant chemotherapy than those
receiving thoracotomy for lobectomy [15].
Cycles of chemotherapy completed, mean dose adminis-
tered and toxicity are the key criteria to evaluate the com-
pliance of chemotherapy. In our study, 73 patients (68.2%)
completed four cycles of chemotherapy, among them
overall 50 patients (45.5%) completed it at full planned
dose on schedule. These numbers was comparable to
those in the published large trials [2,4,16]. When compar-
ing the two groups of different surgical approaches, the
average number of cycles was higher in VATS group, also
more patients in VATS group complete ≥75% planed
dose. This was consistent with the findings that mean
dose administered was also higher in VATS group and
more patients finished four cycles chemotherapy on sche-
dule at full dose in VATS group than in thoracotomy
group. Although higher percentage of patients after VATS
lobectomy received full dose chemotherapy on schedule
was reported [17], this difference could be due to different
patient population, the difference in management of
adverse effects, and the preference of patients and physi-
cians toward chemotherapy’s efficacy and adverse effects.
The better compliance of the chemotherapy in VATS
group was also represented by less severe toxicity in
VATS group. It has been reported that patients after
Table 3 Chemotherapy compliance after lobectomy by
different approach
VATS
n=5 4
Thoracotomy
n=5 6
p
value
Chemotherapy regimens, no. (%) 0.577
Gemcitabine+Cisplatin 25 (46.3) 29 (51.8)
Paclitaxol+Carboplatin 22(40.7) 23(41.1)
Vinorelbine+Cisplatin 7(13.0) 4(7.1)
Time to initiate chemotherapy(days) 33.7 ±
10.9
34.0 ± 13.3 0.904
Cycles completed, (Mean ± SD) 3.6 ±
0.72
3.0 ± 1.1 0.002*
Pts. Receive full dose on schedule,
no. (%)
31 (57.4) 19 (33.9) 0.013
Pts. Receive ≥75% planed dose, no.
(%)
48(88.9) 40(71.4) 0.022*
Mean doses, (% of planed)
Cisplatin (mg/m2) 267
(89.0)
237 (79.0) 0.121
Gemcitabine (mg/m2) 8900
(9.0)
7930 (79.3) 0.120
Paclitaxol (mg/m2) 620
(88.6)
495 (70.7) 0.020*
Carboplatin (AUC mg/ml/min) 21.3
(88.8)
17.0 (70.8) 0.019*
Toxicity, no. (%) 0.011*
Grade 1/2 toxicity 25 (46.3) 34 (60.7) 0.130
Grade 3/4 toxicity 11 (20.4) 20 (35.7) 0.074
Table 4 Grade 3/4 toxicity of chemotherapy according to
NCI-CTC grade
VATS
n=5 4
Thoracotomy
n=5 6
p value
Hematologic,no. (%) 9(16.7) 18(33.3) 0.046*
Leukopenia 5 (9.3) 9 (16.1) 0.284
Neutropenia 7(13.0) 14 (25.0) 0.108
Anemia 1(1.9) 0(0.0) 0.491
Thrombocytopenia 1(1.9) 0(0.0) 0.491
Non-hematologic, no. (%) 6 (11.1) 15(26.8) 0.037*
Nausea 6 (11.1) 14 (25.0) 0.059
Vomiting 3 (5.6) 5(8.9) 0.716
Fatigue/asthenia 1 (1.9) 3 (5.4) 0.618
Diarrhea/constipation 1 (1.9) 2 (3.6) 1.000
Neuropathy: sensory 1 (1.9) 1 (1.8) 1.000
Phlebitis 0 (0.0) 0 (0.0) 1.000
Infection 0 (0.0) 0 (0.0) 1.000
Table 2 Pathological types, postoperative pathologic
staging and postoperative complications of the two
groups of patients
VATS
n=5 4
Thoracotomy
n=5 6
p
value
Operation time (min) 192.0 ± 45.0 238.0 ± 63.7 <0.001*
Blood loss (ml) 225.4 ±
165.1
425.4 ± 261.3 <0.001*
No. of lymph node dissection 14.3 ± 8.8 13.0 ± 5.5 0.245
Chest tube duration (days) 8.0 ± 2.8 9.6 ± 4.4 0.025*
Postoperative length of stay
(days)
10.8 ± 3.7 12.5 ± 4.8 0.043*
Complications, no. (%)
Pneumonia 2(3.7) 5 (8.9) 0.438
Atrial fibrillation 1 (1.9) 7 (12.5) 0.061
Prolonged air leak >7days 0 (0.0) 4 (7.1) 0.118
Others 3 (5.6) 6 (10.7) 0.490
Tumor size (cm) 3.3 ± 1.4 3.8 ± 1.6 0.071
Pathological types, no. (%) <0.001*
Adenocarcinoma 44(81.5) 24(42.9)
Squamous cell carcinoma 8(14.8) 31(55.4)
Others 2(3.7) 1(1.8)
Pathologic staging, no. (%) 0.087
Ib 26 (48.1) 21 (37.5)
II 7(13.0) 17 (30.4)
III 21(38.9) 18 (32.1)
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3 or 4 toxicities than after lobectomies [16]. This means
that extend of resection, or more specifically, the inva-
siveness of the procedure, does affect the tolerance of
adjuvant therapy. Surgical trauma may just increase the
likelihood of toxicity accumulation during adjuvant che-
motherapy, and cause severe adverse effects, perfor-
mance status worsening, and chemotherapy delay and/
or dose reduction, even discontinuation, as a conse-
quence. However, because of limited sample size, this
hypothesized difference failed to reach statistical signifi-
cance in the current study.
Patients receiving VATS have less surgical trauma and
quicker recover; theoretically, these patients may start
postoperative chemotherapy earlier. However, the results
of this study indicated that patients in both groups
started postoperative chemotherapy about 30 days after
surgery. One reason is that there is no difference in
length of stay between the two groups. Another reason
is that we commonly recommend patients start che-
motherapy one month after operation. This time interval
is determined from experience of thoracotomy patients.
In some studies, adjuvant chemotherapy usually initiated
28-50 days postoperatively [4,16]. VATS patients have
quicker recovery and may start adjuvant chemotherapy
earlier. More studies are needed to address this issue,
especially the therapeutic benefit of early-starting adju-
vant chemotherapy.
In an exploratory analysis of JBR10 study, factors
affect compliance included surgery extent, gender and
age [16]. Since these factors, as well as ECOG perfor-
mance status, co-morbidity, pulmonary functions, post-
operative complications and chemotherapy regimens
were comparable between the two groups in this study,
t h ed i f f e r e n c eo fc o m p l i a n c ef o rp o s t o p e r a t i v ec h e -
motherapy can be attributed to the surgical approaches,
namely, better compliance after VATS than thoracot-
omy lobectomy.
Improved survival is the ultimate goal of adjuvant che-
motherapy with better compliance. We next tried to
determine if this better compliance of adjuvant che-
motherapy can translate into better survival. The two
groups have comparable p-stage distribution. However,
the better survival in VATS group could be at least
partly due to more adenocarcinomas. It is elucidated
recently that about half of adenocarcinomas in eastern
Asian patients carry EGFR (epidermal growth factor
receptor) activating mutation, which renders better
prognosis [18,19]. Another bias is more stage Ib patients
in the VATS group, while more stage II of the thoracot-
omy patients. To make discussion about survival more
complicated, if the minimal invasiveness of VATS
lobectomy carries survival benefits for lung cancer is
still controversial due to lacking of randomized trials.
Taken together, no conclusions can be drawn from sur-
vival analysis.
We acknowledge some limitations of this study: retro-
spective in nature, limited sample size, and patients in
the two groups were not perfectly matched.
Conclusions
The compliance to postoperative chemotherapy is better
in patients of VATS group than that in thoracotomy
group. Multicenter prospective study is needed to evalu-
ate in further whether VATS lobectomy has survival
benefit through facilitating adjuvant chemotherapy.
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